OncologyA checkpoint combination extends survival in advanced melanoma
Five-year data suggest durable responses for a third of patients, but toxicity remains the trade-off.
Clara Whitfield · 1 November 2026
Tag
Phase 3
Oncology
NeurologyAmyloid drugs, a second look
New data reopen the debate over who benefits from anti-amyloid antibodies.
Clara Whitfield · 31 October 2026
CardiologyGLP-1 drugs and the heart: what the outcomes trials show
Beyond weight loss, cardiovascular benefits are reshaping prescribing.
Clara Whitfield · 29 October 2026
Trial NewsSeven phase 3 readouts to watch this quarter
From obesity to Alzheimer's, the trials that could move markets.
Clara Whitfield · 26 October 2026